Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis

Yuriko Mori; Vasko Kramer; Emil Novruzov; Eduards Mamlins; Manuel Röhrich; René Fernández; Horacio Amaral; Cristian Soza-Ried; Barbara Monje; Eduardo Sabbagh; Matías Florenzano; Frederik L. Giesel; Álvaro Undurraga

doi:10.1007/s00259-023-06564-y

Initial results with [¹⁸F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis

Yuriko Mori^*, Vasko Kramer, Emil Novruzov, Eduards Mamlins, Manuel Röhrich, René Fernández, Horacio Amaral, Cristian Soza-Ried, Barbara Monje, Eduardo Sabbagh, Matías Florenzano, Frederik L. Giesel, Álvaro Undurraga

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. ⁶⁸Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, ¹⁸F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [¹⁸F]FAPI-74 prospectively in a small patient cohort. Methods: Eight patients underwent both [¹⁸F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters. Results: We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung. Conclusion: The initial results confirm our assumption that [¹⁸F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.

Original language	English
Pages (from-to)	1605-1611
Number of pages	7
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	51
Issue number	6
DOIs	https://doi.org/10.1007/s00259-023-06564-y
State	Published - May 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2023.

Keywords

FAPI
Fibroblast activation protein
Fibrosis
Idiopathic pulmonary disease
PET

Access to Document

10.1007/s00259-023-06564-y

Cite this

Mori, Y., Kramer, V., Novruzov, E., Mamlins, E., Röhrich, M., Fernández, R., Amaral, H., Soza-Ried, C., Monje, B., Sabbagh, E., Florenzano, M., Giesel, F. L., & Undurraga, Á. (2024). Initial results with [¹⁸F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis. European Journal of Nuclear Medicine and Molecular Imaging, 51(6), 1605-1611. https://doi.org/10.1007/s00259-023-06564-y

@article{7aa88e852467456d845a500b712ebd14,

title = "Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis",

abstract = "Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. 68Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, 18F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [18F]FAPI-74 prospectively in a small patient cohort. Methods: Eight patients underwent both [18F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters. Results: We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung. Conclusion: The initial results confirm our assumption that [18F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.",

keywords = "FAPI, Fibroblast activation protein, Fibrosis, Idiopathic pulmonary disease, PET",

author = "Yuriko Mori and Vasko Kramer and Emil Novruzov and Eduards Mamlins and Manuel R{\"o}hrich and Ren{\'e} Fern{\'a}ndez and Horacio Amaral and Cristian Soza-Ried and Barbara Monje and Eduardo Sabbagh and Mat{\'i}as Florenzano and Giesel, \{Frederik L.\} and {\'A}lvaro Undurraga",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2024",

month = may,

doi = "10.1007/s00259-023-06564-y",

language = "English",

volume = "51",

pages = "1605--1611",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "6",

}

Mori, Y, Kramer, V, Novruzov, E, Mamlins, E, Röhrich, M, Fernández, R, Amaral, H, Soza-Ried, C, Monje, B, Sabbagh, E, Florenzano, M, Giesel, FL & Undurraga, Á 2024, 'Initial results with [¹⁸F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis', European Journal of Nuclear Medicine and Molecular Imaging, vol. 51, no. 6, pp. 1605-1611. https://doi.org/10.1007/s00259-023-06564-y

TY - JOUR

T1 - Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis

AU - Mori, Yuriko

AU - Kramer, Vasko

AU - Novruzov, Emil

AU - Mamlins, Eduards

AU - Röhrich, Manuel

AU - Fernández, René

AU - Amaral, Horacio

AU - Soza-Ried, Cristian

AU - Monje, Barbara

AU - Sabbagh, Eduardo

AU - Florenzano, Matías

AU - Giesel, Frederik L.

AU - Undurraga, Álvaro

PY - 2024/5

Y1 - 2024/5

N2 - Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. 68Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, 18F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [18F]FAPI-74 prospectively in a small patient cohort. Methods: Eight patients underwent both [18F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters. Results: We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung. Conclusion: The initial results confirm our assumption that [18F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.

AB - Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. 68Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, 18F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [18F]FAPI-74 prospectively in a small patient cohort. Methods: Eight patients underwent both [18F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters. Results: We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung. Conclusion: The initial results confirm our assumption that [18F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.

KW - FAPI

KW - Fibroblast activation protein

KW - Fibrosis

KW - Idiopathic pulmonary disease

KW - PET

UR - https://www.scopus.com/pages/publications/85180195765

U2 - 10.1007/s00259-023-06564-y

DO - 10.1007/s00259-023-06564-y

M3 - Article

C2 - 38117298

AN - SCOPUS:85180195765

SN - 1619-7070

VL - 51

SP - 1605

EP - 1611

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 6

ER -